SCHEDULE: Adage Capital Boosts Abeona Therapeutics Stake to 9.99%

Adage Capital Management, L.P. and its principals have disclosed a 9.99% beneficial ownership stake in Abeona Therapeutics Inc., including shares from warrants.

Summary

• Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported beneficial ownership of 5,352,996 shares of Abeona Therapeutics Inc. Common Stock.
• This represents 9.99% of the company's outstanding Common Stock.
• The reported ownership includes 2,305,011 shares issuable upon the exercise of warrants.
• The percentage is calculated based on 51,278,539 shares of Common Stock outstanding as of August 8, 2025.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.99% stake by a reputable institutional investor like Adage Capital Management is generally viewed positively, indicating confidence in the company's value or future prospects. The passive nature of the investment (not seeking control) suggests a belief in current management and strategy.

Positives

• A significant institutional investor, Adage Capital Management, L.P., holds a substantial stake (9.99%) in Abeona Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The inclusion of shares from warrants suggests a long-term investment horizon and potential for future capital commitment.

Negatives

• The filing itself does not present explicit negative information about Abeona Therapeutics Inc.

Risks

• The filing does not detail specific risks related to Abeona Therapeutics Inc.'s operations or financial health. It only states the reporting persons' intent for passive investment.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Abeona Therapeutics Inc. regarding its future outlook.

Industry Context

This filing indicates continued institutional interest in Abeona Therapeutics, a biotechnology company. Such significant stakes by investment managers like Adage Capital can be a positive signal within the often volatile biotech sector, suggesting a belief in the company's pipeline or strategic direction.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract further investment, positively impacting share price.
• Management: The passive nature of the investment (not seeking control) suggests Adage Capital is comfortable with the current management and strategic direction.

Key Dates

Recommendation

The filing indicates a significant, passive institutional investment in Abeona Therapeutics by Adage Capital Management. While this signals confidence from a major investor, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a substantial existing stake, suggesting investors should 'hold' and monitor future company performance and Adage's continued involvement.

Keywords

Abeona Therapeutics, Adage Capital Management, Robert Atchinson, Phillip Gross, Common Stock, Warrants, Beneficial Ownership, Schedule 13G, Institutional Investment, Biotechnology, Pharmaceutical